JPMorgan Chase & Co’s Enlivex Therapeutics ENLV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.03K | Sell |
1,814
-99
| -5% | -$111 | ﹤0.01% | 5652 |
|
|
2025
Q1 | $1.86K | Sell |
1,913
-651
| -25% | -$632 | ﹤0.01% | 5679 |
|
|
2024
Q4 | $3K | Buy |
2,564
+750
| +41% | +$878 | ﹤0.01% | 5533 |
|
|
2024
Q3 | $3.05K | Buy |
1,814
+1,583
| +685% | +$2.66K | ﹤0.01% | 5496 |
|
|
2024
Q2 | $328 | Sell |
231
-6,920
| -97% | -$9.83K | ﹤0.01% | 5705 |
|
|
2024
Q1 | $27.1K | Buy |
7,151
+6,914
| +2,917% | +$26.2K | ﹤0.01% | 5159 |
|
|
2023
Q4 | $640 | Sell |
237
-963
| -80% | -$2.6K | ﹤0.01% | 5856 |
|
|
2023
Q3 | $1.9K | Sell |
1,200
-1,179
| -50% | -$1.86K | ﹤0.01% | 5601 |
|
|
2023
Q2 | $6.26K | Buy |
2,379
+2,307
| +3,204% | +$6.07K | ﹤0.01% | 5241 |
|
|
2023
Q1 | $0 | Sell |
72
-26
| -27% | – | ﹤0.01% | 5874 |
|
|
2022
Q4 | $0 | Buy |
+98
| New | – | ﹤0.01% | 5659 |
|
|
2022
Q2 | – | Sell |
-1,152
| Closed | -$6K | – | 5657 |
|
|
2022
Q1 | $6K | Buy |
+1,152
| New | +$6K | ﹤0.01% | 5464 |
|
|
2020
Q2 | – | Sell |
-621
| Closed | -$3K | – | 4782 |
|
|
2020
Q1 | $3K | Buy |
+621
| New | +$3K | ﹤0.01% | 4559 |
|